T wo centuries aer it was first formally described, 1 Parkinson's disease (PD) remains, to clinicians, a challenging juxtaposition of classic knowledge and new understanding. e combination affects perceptions of PD itself, of its treatment, and of unmet management needs.
The Disease Itself
PD continues to be identified clinically 2 by its classic motor features: resting tremor, rigidity, and bradykinesia. Such features all represent dopaminergic dysfunction -more specifically, the progressive loss of nigral dopaminergic afferen tation of the striatum. However, nonmotor symptoms 3 such as depression, fatigue, sleep disorders, and impaired cognition are increasingly recognized as important contributors to the overall healthrelated 3-5 and economic 5-7 burdens imposed on patients and caregivers. 8 Meanwhile, among researchers, descriptions of PD now extend to-and even beyond-a long premotor phase with non-nigral clinical features such as anosmia and dysautonomia. 9 In that sense, patients presenting with PD motor symptoms are not truly "early" in the disease.
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PD Management
In the absence of a curative treatment, or even a proven means of slowing progression, 10 PD therapy continues to be symptomatic, addressing chiefly the patient's motor dysfunction by targeting dopaminergic pathways.
11 Among available strategies, the most effective medication continues to be the dopamine precursor levodopa, 11 routinely coadministered with a peripheral dopa-decarboxylase inhibitor such as carbidopa and also, in some patients, a catechol-Omethyltransferase inhibitor such as entacapone.
12
(Monoamine oxidase-B inhibitors, dopamine agonists, and drugs affecting cholinergic or glutamatergic neurotransmission are also among current treatments.
)
Researchers strongly suspect that the motor complications-fluctuations and dyskinesias-arising in PD patients with chronic levodopa exposure may be the long-term outcomes of the therapy's nonphysiologically intermittent stimulation of striatal dopamine receptors. 13, 14 Hence, for all PD stages, continuous drug delivery is attracting increased attention.
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Illustration. Pharmacokinetic basis for the shortcomings of standard immediate release oral levodopa.
The illustration superimposes a stylized time-course of oscillating plasma drug level (red curve), on the drug's therapeutic window (between the dashed blue lines): the beneficial drug-level range ("On" time). With progressive loss of dopamine neurons, and their capacity to store ("buffer") the neurotransmitter, the window narrows. Drug-level excursions below or above the window permit PD motor symptoms ("Off" time) or cause their own motor complications (eg, peak-dose dyskinesia). Adapted from Olanow CW et al. 2006.
In its standard, immediate-release oral formulation, levodopa requires frequent dosing, owing to a plasma half-life of approximately 1.5 hours (as coadministered with carbidopa).
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Despite the resulting oscillations in plasma drug level, the patient may experience uninterrupted clinical benefit, at least in early PD (see Illustration   16 ). Presumably, this continuity reflects the prodrug's presynaptic conversion, by surviving dopaminergic neurons, into stored dopamine, permitting subsequent release.
11 e brain's capacity for such intraneuronal "buffering" can be expected to decrease as the neurons themselves are lost. Indeed, as PD progresses, the duration of clinical benefit of each levodopa dose diminishes, eventually approximating the transient peripheral bioavailability of the dose itself.
11,17 Oral sustained-release formulations are a potential counterstrategy. However, the continuity of their benefit may be impeded by need for gastric transit, in that levodopa is absorbed only intestinally 18 ; by competition for uptake with dietary amino acids 19 ; and by delay of benefit onset due to the slowed release itself. 20 For their part, several dopamine agonists have peripheral half-lives hours longer than that of levodopa, but they lack its gold-standard efficacy.
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Current Challenges and Treatment Goals
For treatment of PD motor symptoms, the desiderata 22 for levodopa as an oral agent are rapid absorption (for reliable benefit onset) and sustained, stable plasma levels (for prolonged benefit per dose, plus the theoretical advantages of continuous drug delivery: a decreased risk of motor complications and of the hypothesized mechanisms underlying their development). Optimally, the treatment would be beneficial in advanced as well as in early PD. (With progressive loss of dopamine neurons, and their "buffering" capacity, excursions below or above the drug's narrowing therapeutic range permit motor symptoms or may provoke complications.) e treatment would also be beneficial against nonmotor symptoms. 21 In any event, a decrease in medication burden (less frequent dosing or less need for concomitant agents) would increase a treatment's convenience, promoting adherence, 23 which in itself has clinical benefit.
